News and controversy in inflammatory bowel disease treatment

Abstract

Background: The treatment of Inflammatory bowel disease comes from many years of esperience, clinical trials and mistakes.
Discussion: In patients with active Crohn disease steroids are considerated the first choice, but recently, the introduction of anti-TNF alfa agents (infliximab and adalimumab) has changed the protocols. Anti-TNF are also used for closing fistula after surgical curettage. An efficently preventive treatment of Crohn disease still has not been found but hight dose of oral salicylates, azatioprine or 6-MP and antibiotics might be useful. In severe attacks of ulcerative colitis, high dose iv treatment of steroids are required for a few days. Later on, a further treatment with anti- TNF might delay the need of surgery. In patients with mild to moderate attacks of ulcerative colitis, topical treatment is preferred, it consists of enemas, suppositories or foams containing 5-aminosalycilic acid, traditional steroids, topical active steroids. Topical treatment can be associated with oral steroids or oral salicylates. Oral salicylates or azatioprine are used for prevention of relaps.

Downloads

Download data is not yet available.
Published
2013-04-30
Section
Chronic Diseases
Keywords:
Inflammatory bowel disease, Crohn disease, Ulcerative colitis, Fistula.
Statistics
Abstract views: 420

PDF: 570
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Straforini, G., Brugnera, R., Tambasco, R., Rizzello, F., Gionchetti, P., & Campieri, M. (2013). News and controversy in inflammatory bowel disease treatment. Italian Journal of Medicine, 3(3), 179-186. https://doi.org/10.4081/itjm.2009.179